Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Debt (2019 - 2025)

China SXT Pharmaceuticals (SXTC) has 7 years of Total Debt data on record, last reported at $798448.0 in Q1 2025.

  • For Q1 2025, Total Debt rose 30.85% year-over-year to $798448.0; the TTM value through Mar 2025 reached $798448.0, up 30.85%, while the annual FY2025 figure was $798448.0, 30.85% up from the prior year.
  • Total Debt reached $798448.0 in Q1 2025 per SXTC's latest filing, up from $610183.0 in the prior quarter.
  • Across five years, Total Debt topped out at $12.1 million in Q1 2021 and bottomed at $11404.0 in Q1 2022.
  • Average Total Debt over 5 years is $2.7 million, with a median of $610183.0 recorded in 2024.
  • Peak YoY movement for Total Debt: tumbled 99.91% in 2022, then surged 1002.46% in 2023.
  • A 5-year view of Total Debt shows it stood at $12.1 million in 2021, then crashed by 99.91% to $11404.0 in 2022, then soared by 1002.46% to $125725.0 in 2023, then skyrocketed by 385.33% to $610183.0 in 2024, then surged by 30.85% to $798448.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $798448.0 in Q1 2025, $610183.0 in Q1 2024, and $125725.0 in Q1 2023.